Detalles de la búsqueda
1.
Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine.
Ann Gen Psychiatry
; 23(1): 10, 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38424537
2.
Impact of elevated body mass index (BMI) on cognitive functioning and inflammation in persons with post-COVID-19 condition: a secondary analysis.
Acta Neuropsychiatr
; : 1-7, 2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38605630
3.
COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis.
Brain Behav Immun
; 111: 211-229, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36990297
4.
Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Bipolar Disord
; 25(2): 99-109, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36516343
5.
The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia.
CNS Spectr
; 28(5): 541-560, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36268655
6.
Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis.
Brain Behav Immun
; 101: 93-135, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34973396
7.
Lumateperone for the Treatment of Adults With Schizophrenia: a Systematic Review.
Curr Psychiatry Rep
; 24(8): 359-368, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35802228
8.
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
Am J Geriatr Psychiatry
; 29(9): 899-913, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33478865
9.
Corrigendum to "COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis" [Brain Behav. Immun. 111 (2023) 211-229].
Brain Behav Immun
; 115: 758, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37806865
10.
Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.
J Psychopharmacol
; 38(4): 375-381, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38477185
11.
Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
J Affect Disord
; 355: 342-354, 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38570038
12.
A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.
J Affect Disord
; 350: 698-705, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38244804
13.
Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine.
Adv Ther
; 41(5): 1983-1994, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38520501
14.
The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
Expert Opin Pharmacother
; 25(1): 5-14, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38164653
15.
Oral ketamine for depression: An updated systematic review.
World J Biol Psychiatry
; 24(7): 545-557, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36651238
16.
Biomarkers of ketamine's antidepressant effect: An umbrella review.
J Affect Disord
; 323: 598-606, 2023 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36521662
17.
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression.
Neuropharmacology
; 223: 109299, 2023 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36336068
18.
Changes in insulin resistance following antidepressant treatment mediate response in major depressive disorder.
J Psychopharmacol
; 37(3): 313-317, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36377525
19.
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.
Expert Opin Investig Drugs
; 32(5): 401-415, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37096491
20.
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
J Psychopharmacol
; 37(8): 775-783, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37194253